Author Archives: donttradeourlivesaway

TPP and the Dire Threat to Affordable Drug Prices

Drug prices in the U. S. are already approaching a crisis point for many patients unable to afford their prices, often despite being insured. These examples indicate how serious this problem has become:  The use of prescription drugs by Americans, … Continue reading

Posted in Evergreening, TPP, Uncategorized | Leave a comment

Gilead using Data Exclusivity in Ukraine to monopolise Hep-C drug Sofosbuvir

Impact of data exclusivity in Ukraine on access to affordable generic version of sofosbuvir ( direct acting antiviral – DAA used for Hepatitis C treatment)  Chronology of events/facts Pharmasset originally developed Sofosbuvir. Gilead Sciences acquired Pharmasset including its Hepatititis C compounds sofosbuvir for … Continue reading

Posted in Data Exclusivity, Patent, Patent Opposition, TRIPS, TRIPS flexibilities, TRIPS plus, Uncategorized | Leave a comment

The Downfall Of Invention: A Broken Patent System

By Tahir Amin, The Huffington Post | August 17, 2016 The cost of dozens of brand-name drugs have nearly doubled in just the past five years. Public outrage over drug prices extends from Capitol Hill to the presidential candidates to … Continue reading

Posted in Innovation, Patent, TRIPS, Uncategorized | Leave a comment

The Trans Pacific Partnership Agreement and Pharmaceutical Regulation in Canada and Australia

Authors: Joel Lexchin & Deborah Gleeson| Publication: Sage Journals Published online before print August 11, 2016, doi:10.1177/0020731416662612Int J Health Serv August 11, 20160020731416662612 Abstract The Trans Pacific Partnership Agreement (TPP) is a large regional trade agreement involving 12 countries. It was signed in principle … Continue reading

Posted in TPP, Uncategorized | Leave a comment

India Seeks Protection With New Model Bilateral Investment Treaty

By Prabhas Ranjan, The Wire| February 2, 2016 Pricked after being sued by foreign investors under different bilateral investment treaties (BIT), India has adopted a new model. But it could impact the ongoing India-US BIT negotiations. Provoked by foreign investors suing India … Continue reading

Posted in BITS, Compulsory Licensing, TRIPS, Uncategorized, WTO | Leave a comment

Call to remove IP clauses from trade pact

Source: The Hindu | August 16, 2016 Regional Comprehensive Economic Partnership (RCEP) deal could hit supply of cheap Indian drugs As the next round of Regional Comprehensive Economic Partnership (RCEP) trade talks begin in Vietnam on Monday, humanitarian aid organisation … Continue reading

Posted in Data Exclusivity, IPR, Patent Term Extension, Regional Comprehensive Economic Partnership, Uncategorized | Leave a comment

India’s new stance at RCEP may benefit China

India may offer tariff reduction in a much higher number of commodities to China with whom it has a staggering $52.7 billion trade deficit By Asit Ranjan Mishra, Live Mint | August 9, 2016 New Delhi: In a major shift in … Continue reading

Posted in Regional Comprehensive Economic Partnership, Uncategorized | Leave a comment